FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783157829> ?p ?o ?g. }

• W2783157829 endingPage "418" @default.
• W2783157829 startingPage "409" @default.
• W2783157829 abstract "Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study Hui Chang,1,2,* Xin Yu,1,2,* Wei-wei Xiao,1,2 Qiao-xuan Wang,1,2 Wen-hao Zhou,1,3 Zhi-fan Zeng,1,2 Pei-rong Ding,1,3 Li-ren Li,1,3 Yuan-hong Gao1,2 1State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; 2Department of Radiation Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China; 3Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China *These authors contributed equally to this work Background: The prognosis of locally unresectable colon cancer (CC) is poor. This prospective observational study aimed to further evaluate the feasibility and efficacy of neoadjuvant chemoradiotherapy (NACRT) followed by surgery in these patients.Patients and methods: We consecutively enrolled patients who were diagnosed with locally unresectable CC from November 2010 to March 2017, and received NACRT followed by surgery. The data of all the patients were collected prospectively. The R0 resection, downstage and pathologic complete response (pCR) rates were calculated to evaluate the short-term treatment effects. The overall survival (OS) was used to evaluate the long-term outcome. The incidence of NACRT-related acute toxicities and postsurgical complications were used to assess the safety.Results: A total of 60 patients were eligible for analysis, including 57 (95.0%) patients who attained resectability after NACRT. Among patients managed with surgery, 49 cases (86.0%) achieved R0 resection, and 15 cases (26.3%) achieved pCR. Down T stage was seen in 47 cases (82.5%), and down N stage was seen in 53 cases (93.0%). After a median follow-up time of 26 months, the OS appeared as 76.7%. The most common grade 3/4 NACRT-related toxicity was myelosuppression (incidence, 20.0%). The incidence of grade 3/4 surgery-related complication was 7.0%.Conclusion: NACRT might be a safe and effective choice for patients with locally unresectable CC to improve treatment effects, long-term survival and life quality, though further validation is needed. Keywords: colon cancer, unresectable disease, R0 resection, complete response, survival" @default.
• W2783157829 created "2018-01-26" @default.
• W2783157829 creator A5011131515 @default.
• W2783157829 creator A5048846077 @default.
• W2783157829 creator A5061604822 @default.
• W2783157829 creator A5065725300 @default.
• W2783157829 creator A5068654126 @default.
• W2783157829 creator A5071857626 @default.
• W2783157829 creator A5086475800 @default.
• W2783157829 creator A5087378995 @default.
• W2783157829 creator A5089120737 @default.
• W2783157829 date "2018-01-01" @default.
• W2783157829 modified "2023-09-25" @default.
• W2783157829 title "Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study" @default.
• W2783157829 cites W1877186764 @default.
• W2783157829 cites W1943772231 @default.
• W2783157829 cites W1970886073 @default.
• W2783157829 cites W1991222496 @default.
• W2783157829 cites W2026379280 @default.
• W2783157829 cites W2073753331 @default.
• W2783157829 cites W2080193275 @default.
• W2783157829 cites W2087951048 @default.
• W2783157829 cites W2110285036 @default.
• W2783157829 cites W2141704487 @default.
• W2783157829 cites W2200600587 @default.
• W2783157829 cites W2231287974 @default.
• W2783157829 cites W2272984102 @default.
• W2783157829 cites W2291206403 @default.
• W2783157829 cites W2336907809 @default.
• W2783157829 cites W2341169279 @default.
• W2783157829 cites W2460179076 @default.
• W2783157829 cites W2463968935 @default.
• W2783157829 cites W2472421557 @default.
• W2783157829 cites W2506104246 @default.
• W2783157829 cites W2531680521 @default.
• W2783157829 cites W2550449179 @default.
• W2783157829 cites W2578423617 @default.
• W2783157829 cites W2581055553 @default.
• W2783157829 cites W2594546096 @default.
• W2783157829 cites W2595788850 @default.
• W2783157829 cites W2602933474 @default.
• W2783157829 cites W2687302866 @default.
• W2783157829 cites W2746242343 @default.
• W2783157829 doi "https://doi.org/10.2147/ott.s150367" @default.
• W2783157829 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5775742" @default.
• W2783157829 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29398921" @default.
• W2783157829 hasPublicationYear "2018" @default.
• W2783157829 type Work @default.
• W2783157829 sameAs 2783157829 @default.
• W2783157829 citedByCount "18" @default.
• W2783157829 countsByYear W27831578292019 @default.
• W2783157829 countsByYear W27831578292020 @default.
• W2783157829 countsByYear W27831578292021 @default.
• W2783157829 countsByYear W27831578292022 @default.
• W2783157829 countsByYear W27831578292023 @default.
• W2783157829 crossrefType "journal-article" @default.
• W2783157829 hasAuthorship W2783157829A5011131515 @default.
• W2783157829 hasAuthorship W2783157829A5048846077 @default.
• W2783157829 hasAuthorship W2783157829A5061604822 @default.
• W2783157829 hasAuthorship W2783157829A5065725300 @default.
• W2783157829 hasAuthorship W2783157829A5068654126 @default.
• W2783157829 hasAuthorship W2783157829A5071857626 @default.
• W2783157829 hasAuthorship W2783157829A5086475800 @default.
• W2783157829 hasAuthorship W2783157829A5087378995 @default.
• W2783157829 hasAuthorship W2783157829A5089120737 @default.
• W2783157829 hasBestOaLocation W27831578291 @default.
• W2783157829 hasConcept C120665830 @default.
• W2783157829 hasConcept C121332964 @default.
• W2783157829 hasConcept C121608353 @default.
• W2783157829 hasConcept C126322002 @default.
• W2783157829 hasConcept C141071460 @default.
• W2783157829 hasConcept C143998085 @default.
• W2783157829 hasConcept C188816634 @default.
• W2783157829 hasConcept C23131810 @default.
• W2783157829 hasConcept C2778424827 @default.
• W2783157829 hasConcept C509974204 @default.
• W2783157829 hasConcept C526805850 @default.
• W2783157829 hasConcept C61434518 @default.
• W2783157829 hasConcept C61511704 @default.
• W2783157829 hasConcept C71924100 @default.
• W2783157829 hasConceptScore W2783157829C120665830 @default.
• W2783157829 hasConceptScore W2783157829C121332964 @default.
• W2783157829 hasConceptScore W2783157829C121608353 @default.
• W2783157829 hasConceptScore W2783157829C126322002 @default.
• W2783157829 hasConceptScore W2783157829C141071460 @default.
• W2783157829 hasConceptScore W2783157829C143998085 @default.
• W2783157829 hasConceptScore W2783157829C188816634 @default.
• W2783157829 hasConceptScore W2783157829C23131810 @default.
• W2783157829 hasConceptScore W2783157829C2778424827 @default.
• W2783157829 hasConceptScore W2783157829C509974204 @default.
• W2783157829 hasConceptScore W2783157829C526805850 @default.
• W2783157829 hasConceptScore W2783157829C61434518 @default.
• W2783157829 hasConceptScore W2783157829C61511704 @default.
• W2783157829 hasConceptScore W2783157829C71924100 @default.
• W2783157829 hasLocation W27831578291 @default.
• W2783157829 hasLocation W27831578292 @default.
• W2783157829 hasLocation W27831578293 @default.
• W2783157829 hasLocation W27831578294 @default.

• next